Sutro Biopharma, Inc

187 articles about Sutro Biopharma, Inc

• Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

  11/27/2023

  Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) and Sutro Biopharma, Inc. (Sutro) (NASDAQ: STRO) today announced that Vaxcyte has exercised its option and entered into a manufacturing rights agreement with Sutro to obtain control over the development and manufacture of cell-free extract, a key component of Vaxcyte’s pneumococcal conjugate vaccine (PCV) franchise, which includes VAX-24 and VAX-31.

• Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

  11/21/2023

  Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, announced the promotion of Jane Chung to President and Chief Operating Officer, a newly created role, effective December 1, 2023.

• Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

  11/13/2023

  Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the third quarter of 2023, its recent business highlights, and a preview of select anticipated milestones.

• Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

  10/22/2023

  Sutro Biopharma, Inc. announced initial results from a Phase 1 dose-expansion study of luveltamab tazevibulin, a novel Folate receptor alpha -targeting ADC, in patients with endometrial cancer, in a mini oral presentation at the 2023 European Society For Medical Oncology Congress in Madrid, Spain.

• Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

  10/16/2023

  Sutro Biopharma, Inc. announced that the company will have five presentations and one poster at the 14th Annual World ADC Conference, taking place in San Diego, October 16-19, 2023.

• Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

  9/19/2023

  Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023.

• Sutro Biopharma to Participate in Upcoming September 2023 Investor Conferences

  8/30/2023

  Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.

• Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

  8/10/2023

  Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the second quarter of 2023, its recent business highlights, and a preview of select anticipated milestones.

• Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

  6/26/2023

  Sutro Biopharma, Inc. and Blackstone, announced the companies have entered into a royalty financing collaboration agreement where funds managed by Blackstone Life Sciences will provide $140 million upfront.

• Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

  6/3/2023

  Sutro Biopharma, Inc. announced that results from a Phase 1 dose-expansion study of luveltamab tazevibulin, a novel Folate receptor alpha -targeting ADC, in patients with advanced ovarian cancer were featured in an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

• Sutro Biopharma to Participate in the 2023 Jefferies Healthcare Conference

  5/31/2023

  Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 4:30 p.m. ET/1:30 p.m. PT in New York City.

• Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

  5/15/2023

  Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2023, its recent business highlights, and a preview of select anticipated milestones.

• Sutro Biopharma to Present at the JMP Securities Life Sciences Conference - May 08, 2023

  5/8/2023

  Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15th, 2023, at 2:00 p.m. ET / 11:00 a.m. PT in New York City.

• Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

  4/27/2023

  Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO) today announced the Company’s President of Research & Chief Scientific Officer, Trevor Hallam, Ph.D., will be departing from his position effective May 31, 2023 and will immediately join the Company’s Scientific Advisory Board.

• Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

  4/18/2023

  Sutro Biopharma, Inc. today announced expanded preclinical data for STRO-003, its ROR1 targeting ADC, presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held in Orlando, Florida from April 14-19, 2023.

• Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

  3/30/2023

  Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2022, its recent business highlights, and a preview of select anticipated milestones.

• Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 17, 2023

  3/17/2023

  Sutro Biopharma, Inc. announced that on March 1, 2023, the Compensation Committee of Sutro’s Board of Directors granted to Anne Borgman, M.D. 175,000 shares of Sutro Biopharma stock options and 150,000 restricted stock units of Sutro common stock in connection with her appointment as Sutro’s Chief Medical Officer and granted 10,000 RSUs of Sutro common stock to one other new employee.

• Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer  

  2/28/2023

  Sutro Biopharma, Inc. today announced the appointment of Anne Borgman, M.D., as Chief Medical Officer, effective February 28, 2023.

• Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 17, 2023

  2/17/2023

  Sutro Biopharma, Inc. announced that on February 15, 2023, the Compensation Committee of Sutro’s Board of Directors granted 90,000 shares of Sutro Biopharma stock options and 130,000 restricted stock units of Sutro common stock.

• Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer

  1/9/2023

  Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO) today announced results from a Phase 1 dose-expansion study of STRO-002 (luvelta), a novel Folate receptor alpha (FolRα)-targeting ADC and interim safety data from exploratory cohort C, a cohort of 15 patients with advanced ovarian cancer treated at the higher dose of luvelta, (5.2mg/kg), along with prophylactic pegfilgrastim.